Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Reads0
Chats0
TLDR
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.About:
This article is published in The Lancet.The article was published on 2019-07-13. It has received 1449 citations till now. The article focuses on the topics: Dulaglutide & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Portuguese-Brazilian Evidence-Based Guideline on the Management of Hyperglycemia in Type 2 Diabetes Mellitus
Marcello Casaccia Bertoluci,João Eduardo Nunes Salles,José Silva-Nunes,Hermelinda Cordeiro Pedrosa,Rodrigo O. Moreira,R. Duarte,Davide Carvalho,Fábio Rogério Trujilho,João Filipe Raposo,Erika Bezerra Parente,Fernando Valente,Fabio Moura,Alexandre Hohl,Miguel Melo,Francisco Araújo,Rosa Maria Monteiro Castro de Araújo Principe,Rosane Kupfer,Adriana Costa e Forti,Cynthia Melissa Valerio,Hélder José Ferreira,João Manuel Sequeira Duarte,José Francisco Kerr Saraiva,Melanie Rodacki,Maria Helane Costa Gurgel Castelo,Mariana P. Monteiro,Patrícia Branco,Pedro Matos,Pedro Carneiro de Melo Pereira de Magalhães,Roberto Tadeu Barcellos Betti,Rosângela Roginski Réa,Thaisa Dourado Guedes Trujilho,Lana Catani Ferreira Pinto,Cristiane Bauermann Leitão +32 more
TL;DR: The current evidence supports individualizing anti-hyperglycemic treatment for T2DM, and the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control.
Journal ArticleDOI
The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?
Abhipree Sharma,Michael Mah,Rebecca H. Ritchie,Rebecca H. Ritchie,Miles J. De Blasio,Miles J. De Blasio +5 more
TL;DR: In this paper, the authors summarise the current evidence for links between the suppressed adiponectin signalling pathway and cardiac dysfunction, in diabetes, as well as current and potential future therapeutic approaches that could target this pathway as possible interventions for diabetic cardiomyopathy.
Journal ArticleDOI
Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus.
Abraham H. Hulst,Jorinde A. W. Polderman,Sarah E. Siegelaar,Daniel H. van Raalte,J. Hans DeVries,Benedikt Preckel,Jeroen Hermanides +6 more
Journal ArticleDOI
ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release.
Sophia Zoungas,Sophia Zoungas +1 more
TL;DR: This review of four large multicentre, randomized clinical trials of patients with type 2 diabetes provides the most robust evidence of the potential vascular benefits and risks of more versus less glucose control and provides critical insights into how therapies are used.
Journal ArticleDOI
Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.
Enrico Longato,Barbara Di Camillo,Giovanni Sparacino,Lara Tramontan,Angelo Avogaro,Gian Paolo Fadini +5 more
TL;DR: In this article, the authors performed a retrospective study on the administrative database of type 2 diabetes patients from the Veneto Region (North-East Italy) and identified patients who initiated a human-based or exendin-based GLP-1RA from 2011 to 2018.
References
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
Andrew S. Levey,Josef Coresh,Tom Greene,Lesley A. Stevens,Yaping (Lucy) Zhang,Stephen Hendriksen,John W. Kusek,Frederick Van Lente +7 more
TL;DR: The MDRD Study equation has now been reexpressed for use with a standardized serum creatinine assay, allowing GFR estimates to be reported in clinical practice by using standardized serumcreatinine and overcoming this limitation to the current use of GFR estimating equations.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.